<DOC>
	<DOC>NCT02040844</DOC>
	<brief_summary>The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment. The study is an optional follow-up study to a phase III double-blind, placebo controlled, Cat-PAD study; no further investigational product is administered.</brief_summary>
	<brief_title>Phase III Cat-PAD Follow-on Study</brief_title>
	<detailed_description />
	<criteria>previously completed clinical study CP007 [NCT01620762] started allergen therapy since completing CP007 Institutionalised due to a legal or regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>